Decision Aid for Lung Cancer
Trial Summary
What is the purpose of this trial?
This trial tests a tool that helps lung cancer patients understand their treatment options and make decisions with their doctors. It aims to improve patient knowledge, reduce uncertainty, and enhance communication. The study evaluates the tool's effectiveness.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It focuses on decision-making for lung cancer treatment, so it's best to discuss your medications with the trial team.
What data supports the effectiveness of the Decision Aid for Lung Cancer treatment?
Research shows that using decision aids for lung cancer treatment helps patients better understand their treatment options and reduces their uncertainty about making decisions. In a pilot study, patients using a decision aid expressed clear treatment preferences and had less concern about treatment costs.12345
Is the Decision Aid treatment safe for humans?
The Decision Aid treatment, used to help patients make informed choices about their lung cancer treatment options, has been tested in a small group of patients and was found to increase awareness of treatment options and reduce concerns about costs and decision-making uncertainty. However, more studies are needed to fully understand its safety and effectiveness in clinical care.13567
How does the decision aid treatment for lung cancer differ from other treatments?
The decision aid for lung cancer is unique because it focuses on helping patients make informed choices about their treatment options by providing personalized information and supporting shared decision-making with their doctors. Unlike traditional treatments that focus solely on medical interventions, this aid empowers patients to weigh the benefits and risks of different treatments, especially in non-curative settings where quality of life and potential side effects are significant considerations.4891011
Research Team
Donald Sullivan
Principal Investigator
OHSU Knight Cancer Institute
Eligibility Criteria
This trial is for English-speaking individuals with a life expectancy over 6 months who have completed treatment or are undergoing diagnostic work-up for suspected or confirmed stage I-IV non-small cell lung cancer. They must also be cognitively able to participate, as indicated by a score above 3 on a specific cognitive screener.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to receive either the conversation tool or usual care
Follow-up
Participants are monitored for outcomes such as anxiety, decisional conflict, and shared decision-making quality
Treatment Details
Interventions
- Decision Aid
Find a Clinic Near You
Who Is Running the Clinical Trial?
OHSU Knight Cancer Institute
Lead Sponsor
Hildegard Lamfrom Endowment
Collaborator
Medical Research Foundation, Oregon
Collaborator
ATS Foundation
Collaborator
Oregon Health and Science University
Collaborator